BenevolentAI Identifies New Target for Ulcerative Colitis and Proposes Study Candidate for IND / CTA
– The Benevolent PlatformTM for AI-based Drug Discovery identified and validated a new biological target that was previously unrelated to disease
Posted: October 14, 2021 at 4:00 a.m. EDT|Update: 1 hour ago
LONDON, October 14, 2021 / PRNewswire / – In a milestone for its AI-powered drug discovery platform, Benevolent AI has appointed a preclinical candidate for a novel ulcerative colitis target and plans to advance the asset into clinical trials.
Scientists deployed BenevolentAI’s powerful target identification tools and machine learning models to identify and experimentally validate a new biological target without prior reference in published literature or patents linking the gene to ulcerative colitis. BenevolentAI used its advanced molecular design capabilities to generate a potential first-order, oral and peripheral-limited drug candidate within two years of target validation. The preclinical candidate has been validated experimentally in ex-vivo ulcerative colitis samples from patients who did not respond to standard therapy.
BenevolentAI plans to move the program to the clinic in early 2023. The company is currently applying its AI models of precision medicine to inform clinical trial design, trained on data from ulcerative colitis patients to target key cohorts. responder patients and identify efficacy biomarkers.
Anne Phelan, Scientific Director of BenevolentAI, commented, âUlcerative colitis is a lifelong chronic disease that affects 0.2% of the US population alone and 1.6 million patients in the 7 major markets, but it is underserved by standard therapies. the new preclinical candidate addresses the high unmet need for oral, safe and effective therapy and has demonstrated an improved safety and tolerability profile compared to other major treatments for IBD. We are actively using molecular descriptors derived from patients to target patient subgroups that will optimize trial design further increase our chances of success. “
Joanna shields, CEO of BenevolentAI, commented: âThe nomination of a drug candidate for a new ulcerative colitis target identified by our AI drug discovery platform represents a significant milestone for BenevolentAI, but more importantly it makes advancing a potential new treatment for this debilitating disease. “
This latest milestone in ulcerative colitis further validates Benevolent’s AI platform and drug discovery expertise in identifying new targets for complex multifactorial diseases. In early 2021, a new AI-generated target was selected for AstraZeneca portfolio in CKD, along with other expected targets in IPF. The ulcerative colitis program is part of a rapidly evolving pipeline of more than 20 internal programs, including one asset in clinical trials for atopic dermatitis. The company also discovered Eli Lilly’s baricitinib as a treatment for COVID-19 – a new drug reorientation hypothesis that is now clinically validated and FDA approved. As of 2021, BenevolentAI has been the only AI-augmented drug discovery company whose drug discovery platform and approach has been validated by computer, experimentally and clinically.
BenevolentAI combines advanced AI and machine learning with cutting-edge science to decipher the complex biology of disease, generate new information, and discover more effective drugs. Our unique R&D IT platform covers every step of the drug discovery process, fueling an internal pipeline of more than 20 drug programs, from early discovery to clinical phases. Along with several successful collaborations with leading pharmaceutical organizations, we are also the only AI drug discovery company with a clinically validated approach, discovering a leading reconverted drug candidate for COVID-19. BenevolentAI is headquartered in London with a research center in Cambridge (United Kingdom) and another office in new York, with a team of over 300 world-renowned scientists and technologists advancing its mission to reinvent drug discovery and advance life-changing drugs to the clinic.
+44 (0)7732 603 108
Show original content:
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.